Other Solid Tumors Clinical Trial
Official title:
Phase IB Followed by Phase II Study of Trastuzumab Combined With Autologous Chimeric Receptor T Cells in HER2+ Advanced Breast Cancer and Other Solid Tumors
This phase Ib study aims to assess the safety and feasibility of combination of chimeric receptor T cells with trastuzumab in patients with HER2+ solid tumors, with further expansion of study population in HER2+ metastatic breast cancer once safety has been established.
Hypothesis Investigators hypothesize that trastuzumab-mediated cytotoxicity will be augmented by the infusion of autologous chimeric receptor T-cells. Primary Objectives 1. To determine the safety of autologous chimeric receptor T-cells in patients with HER2+ advanced solid tumors 2. To determine the clinical benefit rate (CBR) of autologous chimeric receptor T-cells in patients with HER2+ advanced breast cancer Secondary Objectives 1. To determine the expansion and persistence of autologous chimeric receptor T-cells after a single infusion in patients with advanced solid tumors 2. To determine anti-tumor efficacy in terms of objective response rate (ORR) and progression-free survival (PFS) of autologous chimeric receptor T-cells in patients with HER2+ advanced breast cancer ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04045496 -
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT02709889 -
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06022757 -
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05332574 -
A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05788484 -
A Study of CDX-585 in Patients With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT04834778 -
A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)
|
Phase 1 | |
| Recruiting |
NCT03947385 -
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
|
Phase 1/Phase 2 | |
| Completed |
NCT02819843 -
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT04121286 -
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
|
Phase 1 | |
| Recruiting |
NCT05877599 -
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
|
Phase 1 | |
| Recruiting |
NCT05631964 -
Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
|
Phase 1 | |
| Terminated |
NCT02607813 -
Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
|
Phase 1 | |
| Recruiting |
NCT04256707 -
Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
|
Phase 1/Phase 2 | |
| Terminated |
NCT05121948 -
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
|
Phase 1 | |
| Recruiting |
NCT05393427 -
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
|
Phase 1 | |
| Completed |
NCT02573259 -
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
|
Phase 1 | |
| Terminated |
NCT00064636 -
Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
|
Phase 1 | |
| Completed |
NCT03329950 -
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT04440943 -
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT02404441 -
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
|
Phase 1/Phase 2 |